Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Phase III REZILIENT-3 reports median progression-free survival of 14.5 months with zipalertinib plus chemotherapy versus 8.5 months with chemotherapy alone in first-line EGFR exon 20 insertion mutation NSCLC, with CNS efficacy in brain metastases and manageable safety.
Phase 3 REZILIENT 3 reported that zipalertinib plus chemotherapy significantly improved progression-free survival and response rates versus chemotherapy alone in metastatic EGFR exon 20 insertion NSCLC.
In first-line EGFR exon 20 insertion mutation NSCLC, zipalertinib plus chemotherapy showed significantly improved median progression-free survival and response rates versus chemotherapy alone, with a manageable safety profile.